The strong beat and guidance raise confirm accelerating royalty momentum, while the XOMA close and $700M deployable capital signal a larger, more diversified platform. Monitor Q3 for initial XOMA contribution and any further royalty acquisitions; the $524.34 warrant strike caps near-term dilution risk.
Drugs in focus
LGND drug pipeline →Ersodetug
● Neutral Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If the full upLIFT results (expected mid-December 2026) remain positive, Rezolute could file a Biologics License Application (BLA) for tumor hyperinsulinism in 2027. The congenital HI path is less clear after the sunRIZE miss, though the FDA has recommended a pre-BLA meeting. Analyst projections from 2025 suggested a potential market launch in 2027 for at least one indication.
- Next catalyst
- None dated
What to watchThe next hard catalyst for ersodetug is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. Positive results would support a BLA filing for tumor HI, while the congenital HI path remains uncertain after the sunRIZE miss. For LGND holders, this is a minor portfolio contributor; for RZLT holders, it is the primary value driver.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $300.14entry
- T+1 · 3mo ago −2.33%α −2.94% · $293.15
- T+5 · 3mo ago −3.77%α −4.98% · $288.82
- T+20 · 3mo ago −3.46%α −4.06% · $289.74
- T+60 · 18d ago +7.53%α +9.20% · $322.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs consensus of $1.97, driven by 32% YoY royalty revenue growth to $48.0M. The company raised the low end of its 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50) and closed the XOMA Royalty acquisition on July 14, 2026, adding over 120 assets. The strong beat, guidance raise, and transformative acquisition close are clearly positive, but the $700M convertible debt issuance and share repurchase at ~$262 introduce modest dilution and capital structure complexity.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS of $2.37 beat consensus of $1.97 by 20.3%
- Q2 2026 total revenue of $63.7M beat consensus of $61.3M by 3.9%
- Royalty revenue grew 32% YoY to $48.0M, driven by Filspari, Zelsuvmi, and Ohtuvayre
- Raised low end of 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50); revenue guidance unchanged at $270M-$310M
- Closed XOMA Royalty acquisition on July 14, 2026, adding >120 assets for $39.00/share plus CVR
- Completed $700M 0.00% convertible note offering due 2031; used ~$60M to repurchase 228,859 shares at ~$262/share
- Cash, cash equivalents, and short-term investments were $1.36B at June 30, 2026, up from $733.5M at Dec 31, 2025
- Filspari (Travere) Q2 net sales grew 96% YoY to $141M, driven by FSGS launch and IgAN growth
Financial Impact
Adjusted EPS beat consensus by $0.40 (20.3%); revenue beat by $2.4M (3.9%); guidance raised by $0.50 at low end
Risk Factors
- Integration risk from XOMA acquisition; potential for higher-than-expected operating costs
- Dependence on partner commercial execution (Filspari, Ohtuvayre, Capvaxive) for royalty growth
- Convertible debt ($1.13B net) increases leverage; dilution risk if stock exceeds $524.34
- Captisol sales declining (down 4% YoY in Q2) and subject to customer order timing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000886163-26-000041 |
| Document: lgnd-20260806.htm | 0000886163-26-000041 |
| Document: 0000886163-26-000041-index-headers.html | 0000886163-26-000041 |
| Document: 0000886163-26-000041-index.html | 0000886163-26-000041 |
| Document: 0000886163-26-000041.txt | 0000886163-26-000041 |
| 8-K Data (Synthetic) | 0000886163-26-000041 |
Track record
29 reports on LGND
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers